Home News

First nine months 2020 results presentation

Operating income, growth figures, profitability and how our products have behaved.

Thu, 05/11/2020 - 00:00 0 min
Download related document
No votes yet
 
Related
The FDA delays its decision on Risperidone ISM®
The FDA delays its decision on Risperidone ISM®
The FDA delays its decision on Risperidone ISM® Madrid – 21 October, 2021 – Laboratorios Farmacéuticos Rovi, S.A. (“ROVI” or the “...
2 min
21/10/2021
ROVI informa del comunicado conjunto de Moderna y Takeda en relación con la investigación sobre los lotes bloqueados de la vacuna
ROVI informs about the joint statement from Moderna and Takeda on the...
Following the public relevant information published on 26 and on 29 of August 2021 with registered numbers 11377 and 11399 respectively,...
4 min
01/09/2021
ROVI informs on the evolution of the investigation of particulate matter having...
Following the public relevant information published on 26 of August 2021 with registered number 11377, Laboratorios Farmacéuticos ROVI, S.A...
2 min
29/08/2021